(S)-prasugrel (BioDeep_00000847527)
代谢物信息卡片
(S)-prasugrel
化学式: C20H20FNO3S (373.1147862)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4
InChI: InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3/t19-/m0/s1
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Laura M Dechant. UA/NSTEMI: Are you following the latest guidelines?.
Nursing.
2012 Sep; 42(9):26-33; quiz 34. doi:
10.1097/01.nurse.0000418611.61100.ca. [PMID: 22889948] - Christopher N Floyd, Gabriella Passacquale, Albert Ferro. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Clinical pharmacokinetics.
2012 Jul; 51(7):429-42. doi:
10.2165/11630740-000000000-00000. [PMID: 22568693] - Licia Totani, Giuseppe Dell'Elba, Nicola Martelli, Angelomaria Di Santo, Antonio Piccoli, Concetta Amore, Virgilio Evangelista. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse.
Thrombosis and haemostasis.
2012 Jun; 107(6):1130-40. doi:
10.1160/th11-12-0867. [PMID: 22436970] - Renli Teng. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
Clinical pharmacokinetics.
2012 May; 51(5):305-18. doi:
10.2165/11630960-000000000-00000. [PMID: 22489610] - Eugene Braunwald. Unstable angina and non-ST elevation myocardial infarction.
American journal of respiratory and critical care medicine.
2012 May; 185(9):924-32. doi:
10.1164/rccm.201109-1745ci. [PMID: 22205565] - David P Faxon. Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention.
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
2012 Feb; 79(2):181-97. doi:
10.1002/ccd.23163. [PMID: 21618679] - Ojikumar Lukram, Mukund Zarapkar, Chandan Kumar Jha, Shivaji Parmar, Keshav S Tomar, Amit Hande. Electrospray ionization LC-MS/MS validated method for the determination of the active metabolite (R-138727) of prasugrel in human plasma and its application to a bioequivalence study.
Drug testing and analysis.
2012 Feb; 4(2):158-66. doi:
10.1002/dta.264. [PMID: 21438161] - Karsten Schrör, Jolanta M Siller-Matula, Kurt Huber. Pharmacokinetic basis of the antiplatelet action of prasugrel.
Fundamental & clinical pharmacology.
2012 Feb; 26(1):39-46. doi:
10.1111/j.1472-8206.2011.00986.x. [PMID: 21895761] - Yue Liu, Hui-Jun Yin, Da-Zhuo Shi, Ke-Ji Chen. Chinese herb and formulas for promoting blood circulation and removing blood stasis and antiplatelet therapies.
Evidence-based complementary and alternative medicine : eCAM.
2012; 2012(?):184503. doi:
10.1155/2012/184503. [PMID: 22454656] - Daniel Duerschmied, Ingo Ahrens, Maximilian Mauler, Christoph Brandt, Stefanie Weidner, Christoph Bode, Martin Moser. Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.
PloS one.
2012; 7(2):e32656. doi:
10.1371/journal.pone.0032656. [PMID: 22384279] - Shantu S Bundhoo, Richard A Anderson, Ewelina Sagan, Nurudeen Hassan, Andrew G Pinder, Stephen C Rogers, Keith Morris, Philip E James. Direct formation of thienopyridine-derived nitrosothiols--just add nitrite!.
European journal of pharmacology.
2011 Nov; 670(2-3):534-40. doi:
10.1016/j.ejphar.2011.09.022. [PMID: 21946108] - Sukhdeep S Basra, Peter Tsai, Nasser M Lakkis. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Journal of the American College of Cardiology.
2011 Nov; 58(22):2263-9. doi:
10.1016/j.jacc.2011.08.051. [PMID: 22093501] - Lynn M Abell, Eddie C-K Liu. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
The Journal of pharmacology and experimental therapeutics.
2011 Nov; 339(2):589-96. doi:
10.1124/jpet.111.184895. [PMID: 21828263] - P D M Leadbeater, N S Kirkby, S Thomas, A-R Dhanji, A T Tucker, G L Milne, J A Mitchell, T D Warner. Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel.
Journal of thrombosis and haemostasis : JTH.
2011 Oct; 9(10):2050-6. doi:
10.1111/j.1538-7836.2011.04450.x. [PMID: 21794076] - Kenneth A Jacobson, Francesca Deflorian, Shilpi Mishra, Stefano Costanzi. Pharmacochemistry of the platelet purinergic receptors.
Purinergic signalling.
2011 Sep; 7(3):305-24. doi:
10.1007/s11302-011-9216-0. [PMID: 21484092] - Katsunobu Hagihara, Miho Kazui, Hidenori Ikenaga, Toshihiko Nanba, Kiichi Fusegawa, Takashi Izumi, Toshihiko Ikeda, Atsushi Kurihara. The intestine as an important contributor to prasugrel active metabolite formation in vivo.
Drug metabolism and disposition: the biological fate of chemicals.
2011 Apr; 39(4):565-70. doi:
10.1124/dmd.110.035956. [PMID: 21189331] - P C J Armstrong, P D Leadbeater, M V Chan, N S Kirkby, J A Jakubowski, J A Mitchell, T D Warner. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation.
Journal of thrombosis and haemostasis : JTH.
2011 Mar; 9(3):552-61. doi:
10.1111/j.1538-7836.2010.04160.x. [PMID: 21143373] - David Iyú, Jackie R Glenn, Ann E White, Sue C Fox, Stan Heptinstall. Adenosine derived from ADP can contribute to inhibition of platelet aggregation in the presence of a P2Y12 antagonist.
Arteriosclerosis, thrombosis, and vascular biology.
2011 Feb; 31(2):416-22. doi:
10.1161/atvbaha.110.219501. [PMID: 21106949] - Horst Neubauer, Andreas F C Kaiser, Heinz G Endres, Jan C Krüger, Andreas Engelhardt, Sebastian Lask, Fenena Pepinghege, Andreas Kusber, Andreas Mügge. Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance--the BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy.
BMC medicine.
2011 Jan; 9(?):3. doi:
10.1186/1741-7015-9-3. [PMID: 21226927] - Analia E Garcia, Sripal R Mada, Mario C Rico, Raul A Dela Cadena, Satya P Kunapuli. Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis.
PloS one.
2011; 6(10):e26035. doi:
10.1371/journal.pone.0026035. [PMID: 22028806] - Melissa V Chan, Paul C J Armstrong, Francesco Papalia, Nicholas S Kirkby, Timothy D Warner. Optical multichannel (optimul) platelet aggregometry in 96-well plates as an additional method of platelet reactivity testing.
Platelets.
2011; 22(7):485-94. doi:
10.3109/09537104.2011.592958. [PMID: 21806492] - Dan Seiler, Karlheinz Doser, Isam Salem. Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor.
Arzneimittel-Forschung.
2011; 61(4):247-51. doi:
10.1055/s-0031-1296195. [PMID: 21650084] - Joseph A Jakubowski, Chunmei Zhou, Blaine Egan, Maggie Wells, Maya Kotob-Yahfoufi, Atsuhiro Sugidachi, Jeffrey R Dahlen. Modification of the VerifyNow® P2Y12 test BASE channel to accommodate high levels of P2Y(12) antagonism.
Platelets.
2011; 22(8):619-25. doi:
10.3109/09537104.2011.579203. [PMID: 21639823] - David S Small, Nagy A Farid, Christopher D Payne, Christopher S Konkoy, Joseph A Jakubowski, Kenneth J Winters, Daniel E Salazar. Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.
Clinical pharmacokinetics.
2010 Dec; 49(12):777-98. doi:
10.2165/11537820-000000000-00000. [PMID: 21053990] - Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Joseph R Walker, Tabassome Simon, Elliott M Antman, Eugene Braunwald, Marc S Sabatine. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Lancet (London, England).
2010 Oct; 376(9749):1312-9. doi:
10.1016/s0140-6736(10)61273-1. [PMID: 20801494] - Joseph A Jakubowski, Ying G Li, David S Small, Christopher D Payne, Molly E Tomlin, Junxiang Luo, Kenneth J Winters. A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Journal of cardiovascular pharmacology.
2010 07; 56(1):29-37. doi:
10.1097/fjc.0b013e3181dd0ec2. [PMID: 20386460] - Federico M Goodsaid, Shashi Amur, Jiri Aubrecht, Michael E Burczynski, Kevin Carl, Jennifer Catalano, Rosane Charlab, Sandra Close, Catherine Cornu-Artis, Laurent Essioux, Albert J Fornace, Lois Hinman, Huixiao Hong, Ian Hunt, David Jacobson-Kram, Ansar Jawaid, David Laurie, Lawrence Lesko, Heng-Hong Li, Klaus Lindpaintner, James Mayne, Peter Morrow, Marisa Papaluca-Amati, Timothy W Robison, John Roth, Ina Schuppe-Koistinen, Leming Shi, Olivia Spleiss, Weida Tong, Sharada L Truter, Jacky Vonderscher, Agnes Westelinck, Li Zhang, Issam Zineh. Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact.
Nature reviews. Drug discovery.
2010 06; 9(6):435-45. doi:
10.1038/nrd3116. [PMID: 20514070] - Lars Maegdefessel, Joshua M Spin, Junya Azuma, Philip S Tsao. New options with dabigatran etexilate in anticoagulant therapy.
Vascular health and risk management.
2010 May; 6(?):339-49. doi:
10.2147/vhrm.s8942. [PMID: 20531953] - Shaker A Mousa, Walter P Jeske, Jawed Fareed. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
2010 Apr; 16(2):170-6. doi:
10.1177/1076029609355589. [PMID: 20299391] - Robert B Parker, S Casey Laizure. The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Feb; 38(2):317-22. doi:
10.1124/dmd.109.030056. [PMID: 19920055] - David S Small, Christopher D Payne, Prajakti Kothare, Eunice Yuen, Fanni Natanegara, Mei Teng Loh, Joseph A Jakubowski, D Richard Lachno, Ying G Li, Kenneth J Winters, Nagy A Farid, Lan Ni, Daniel E Salazar, Molly Tomlin, Ronan Kelly. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
Clinical therapeutics.
2010 Feb; 32(2):365-79. doi:
10.1016/j.clinthera.2010.02.015. [PMID: 20206794] - David S Small, Prajakti Kothare, Eunice Yuen, D Richard Lachno, Ying G Li, Kenneth J Winters, Nagy A Farid, Lan Ni, Joseph A Jakubowski, Daniel E Salazar, Vivian T Thieu, Christopher D Payne. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.
European journal of clinical pharmacology.
2010 Feb; 66(2):127-35. doi:
10.1007/s00228-009-0737-1. [PMID: 19888568] - Kamala Bhavaraju, Alexander Georgakis, Jianguo Jin, Theodore Kent Gartner, Yoshiaki Tomiyama, Alan Nurden, Paquita Nurden, Satya P Kunapuli. Antagonism of P2Y₁₂ reduces physiological thromboxane levels.
Platelets.
2010; 21(8):604-9. doi:
10.3109/09537104.2010.511684. [PMID: 21067313] - Victor L Serebruany. Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.
Cardiology.
2010; 117(3):231-3. doi:
10.1159/000322789. [PMID: 21212672] - Shaker A Mousa, Walter P Jeske, Jawed Fareed. Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist.
Methods in molecular biology (Clifton, N.J.).
2010; 663(?):221-8. doi:
10.1007/978-1-60761-803-4_8. [PMID: 20617420] - D S Small, R E Wrishko, C S Ernest, L Ni, K J Winters, N A Farid, Y G Li, J T Brandt, D E Salazar, A G Borel, K A Kles, C D Payne. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.
Journal of clinical pharmacy and therapeutics.
2009 Oct; 34(5):585-94. doi:
10.1111/j.1365-2710.2009.01068.x. [PMID: 19744014] - Paul P Dobesh. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Pharmacotherapy.
2009 Sep; 29(9):1089-102. doi:
10.1592/phco.29.9.1089. [PMID: 19698014] - Christoph Varenhorst, Stefan James, David Erlinge, John T Brandt, Oscar O Braun, Michael Man, Agneta Siegbahn, Joseph Walker, Lars Wallentin, Kenneth J Winters, Sandra L Close. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
European heart journal.
2009 Jul; 30(14):1744-52. doi:
10.1093/eurheartj/ehp157. [PMID: 19429918] - Jessica L Mega, Sandra L Close, Stephen D Wiviott, Lei Shen, Richard D Hockett, John T Brandt, Joseph R Walker, Elliott M Antman, William L Macias, Eugene Braunwald, Marc S Sabatine. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Circulation.
2009 May; 119(19):2553-60. doi:
10.1161/circulationaha.109.851949. [PMID: 19414633] - K Hagihara, M Kazui, H Ikenaga, T Nanba, K Fusegawa, M Takahashi, A Kurihara, O Okazaki, N A Farid, T Ikeda. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
Xenobiotica; the fate of foreign compounds in biological systems.
2009 Mar; 39(3):218-26. doi:
10.1080/00498250802650077. [PMID: 19280520] - Kenneth A Jacobson, Andrei A Ivanov, Sonia de Castro, T Kendall Harden, Hyojin Ko. Development of selective agonists and antagonists of P2Y receptors.
Purinergic signalling.
2009 Mar; 5(1):75-89. doi:
10.1007/s11302-008-9106-2. [PMID: 18600475] - David S Small, Rebecca E Wrishko, C Steven Ernest, Lan Ni, Kenneth J Winters, Nagy A Farid, Ying G Li, Daniel E Salazar, Christopher D Payne. Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.
Drugs & aging.
2009; 26(9):781-90. doi:
10.2165/11315780-000000000-00000. [PMID: 19728751] - Steen Husted, J J J van Giezen. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Cardiovascular therapeutics.
2009; 27(4):259-74. doi:
10.1111/j.1755-5922.2009.00096.x. [PMID: 19604248] - David Erlinge, Christoph Varenhorst, Oscar O Braun, Stefan James, Kenneth J Winters, Joseph A Jakubowski, John T Brandt, Atsuhiro Sugidachi, Agneta Siegbahn, Lars Wallentin. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Journal of the American College of Cardiology.
2008 Dec; 52(24):1968-77. doi:
10.1016/j.jacc.2008.07.068. [PMID: 19055987] - Nagy A Farid, David S Small, Christopher D Payne, Joseph A Jakubowski, John T Brandt, Ying G Li, C Steven Ernest, Daniel E Salazar, Christopher S Konkoy, Kenneth J Winters. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Pharmacotherapy.
2008 Dec; 28(12):1483-94. doi:
10.1592/phco.28.12.1483. [PMID: 19025429] - C Steven Ernest, David S Small, Shashank Rohatagi, Daniel E Salazar, Lars Wallentin, Kenneth J Winters, Rebecca E Wrishko. Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Journal of pharmacokinetics and pharmacodynamics.
2008 Dec; 35(6):593-618. doi:
10.1007/s10928-008-9103-7. [PMID: 19023649] - David S Small, Nagy A Farid, Ying G Li, C Steven Ernest, Christopher D Payne, Daniel E Salazar, Kenneth J Winters. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Current medical research and opinion.
2008 Aug; 24(8):2251-7. doi:
10.1185/03007990802205985. [PMID: 18786302] - Eric T Williams, Karen O Jones, G Douglas Ponsler, Shane M Lowery, Everett J Perkins, Steven A Wrighton, Kenneth J Ruterbories, Miho Kazui, Nagy A Farid. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1227-32. doi:
10.1124/dmd.107.020248. [PMID: 18372401] - Heather M Judge, Robert J Buckland, Atsuhiro Sugidachi, Joseph A Jakubowski, Robert F Storey. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Platelets.
2008 Mar; 19(2):125-33. doi:
10.1080/09537100701694144. [PMID: 18297550] - Christian Storm, Achim Jörres. Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?.
Critical care (London, England).
2008; 12(6):193. doi:
10.1186/cc7083. [PMID: 19040776] - J T Brandt, S L Close, S J Iturria, C D Payne, N A Farid, C S Ernest, D R Lachno, D Salazar, K J Winters. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Journal of thrombosis and haemostasis : JTH.
2007 Dec; 5(12):2429-36. doi:
10.1111/j.1538-7836.2007.02775.x. [PMID: 17900275] - R L Smith, T A Gillespie, T J Rash, A Kurihara, N A Farid. Disposition and metabolic fate of prasugrel in mice, rats, and dogs.
Xenobiotica; the fate of foreign compounds in biological systems.
2007 Aug; 37(8):884-901. doi:
10.1080/00498250701485542. [PMID: 17701835] - Andrew L Frelinger, Joseph A Jakubowski, Youfu Li, Marc R Barnard, Marsha L Fox, Matthew D Linden, Atsuhiro Sugidachi, Kenneth J Winters, Mark I Furman, Alan D Michelson. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin.
Thrombosis and haemostasis.
2007 Jul; 98(1):192-200. doi:
10.1160/th07-01-0010. [PMID: 17598013] - A Sugidachi, T Ogawa, A Kurihara, K Hagihara, J A Jakubowski, M Hashimoto, Y Niitsu, F Asai. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Journal of thrombosis and haemostasis : JTH.
2007 Jul; 5(7):1545-51. doi:
10.1111/j.1538-7836.2007.02598.x. [PMID: 17456192] - Nagy A Farid, Richard L Smith, Todd A Gillespie, T James Rash, Patrick E Blair, Atsushi Kurihara, Mark J Goldberg. The disposition of prasugrel, a novel thienopyridine, in humans.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Jul; 35(7):1096-104. doi:
10.1124/dmd.106.014522. [PMID: 17403916] - K Hagihara, A Kurihara, K Kawai, M Kazui, M Takahashi, K Kawabata, N A Farid, T Ikeda. Absorption, distribution and excretion of the new thienopyridine agent prasugrel in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2007 Jul; 37(7):788-801. doi:
10.1080/00498250701397721. [PMID: 17620223] - Enaksha R Wickremsinhe, Ye Tian, Kenneth J Ruterbories, Elizabeth M Verburg, Govinda J Weerakkody, Atsushi Kurihara, Nagy A Farid. Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.
Drug metabolism and disposition: the biological fate of chemicals.
2007 Jun; 35(6):917-21. doi:
10.1124/dmd.106.014530. [PMID: 17353347] - N A Farid, C D Payne, D S Small, K J Winters, C S Ernest, J T Brandt, C Darstein, J A Jakubowski, D E Salazar. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Clinical pharmacology and therapeutics.
2007 May; 81(5):735-41. doi:
10.1038/sj.clpt.6100139. [PMID: 17361128] - Nagy A Farid, Mary McIntosh, Fabio Garofolo, Ernest Wong, Amanda Shwajch, Monika Kennedy, Michelle Young, Pratibha Sarkar, Kiyoshi Kawabata, Makoto Takahashi, Henrianna Pang. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM.
2007; 21(2):169-79. doi:
10.1002/rcm.2813. [PMID: 17154350] - John T Brandt, Christopher D Payne, Stephen D Wiviott, Govinda Weerakkody, Nagy A Farid, David S Small, Joseph A Jakubowski, Hideo Naganuma, Kenneth J Winters. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
American heart journal.
2007 Jan; 153(1):66.e9-16. doi:
10.1016/j.ahj.2006.10.010. [PMID: 17174640] - Nobuko Matsushima, Joseph A Jakubowski, Fumitoshi Asai, Hideo Naganuma, John T Brandt, Takashi Hirota, Stephen Freestone, Kenneth J Winters. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a multiple-dose study in healthy humans.
Platelets.
2006 Jun; 17(4):218-26. doi:
10.1080/09537100600565510. [PMID: 16769599] - Fumitoshi Asai, Joseph A Jakubowski, Hideo Naganuma, John T Brandt, Nobuko Matsushima, Takashi Hirota, Stephen Freestone, Kenneth J Winters. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans.
Platelets.
2006 Jun; 17(4):209-17. doi:
10.1080/09537100600565551. [PMID: 16769598]